BPG is committed to discovery and dissemination of knowledge
Retrospective Study
©The Author(s) 2025.
World J Gastrointest Surg. Dec 27, 2025; 17(12): 113029
Published online Dec 27, 2025. doi: 10.4240/wjgs.v17.i12.113029
Table 2 Patient demographics and perioperative characteristics stratified by survival outcome, mean ± SD/n (%)/median (interquartile range)
Characteristic
Total (n = 88)
PPH survival group (n = 64)
PPH mortality group (n = 24)
P value
Age, years64.0 ± 9.962.6 ± 9.967.6 ± 90.028
Gender0.218
    Male56 (63.6)38 (59.4)18 (75)
    Female32 (36.4)26 (40.6)6 (25)
Hypertension43 (48.9)35 (54.7)8 (33.3)0.095
Diabetes11 (12.5)5 (7.8)6 (25)0.063
In-hospital days45 (36.5-63.25)50 (38-64.25)39 (24.25-51.5)0.01
Pathology diagnosis0.223
PDCA23 (26.1)16 (25.0)7 (29.2)
CBD cancer34 (38.6)21 (32.8)13 (54.2)
Ampullary cancer5 (5.7)4 (6.2)1 (4.2)
Duodenal cancer13 (14.8)10 (15.6)3 (12.5)
    Other malignancies7 (8.0)7 (10.9)0 (0)
    Other benign disease6 (6.8)6 (9.4)0 (0)
Preoperative total bilirubin (mmol/L)62.1 (19.8-127.2)62.5 (19-131.1)62.0 (20.7-119.5)0.892
Preoperative direct bilirubin (mmol/L)42.5 (14.2-101.1)48.0 (13.6-108)39.5 (17.1-72.2)0.818
Operating duration (minutes)655.0 (540.0-753.8)610.0 (498.8-727.5)697.5 (611.2-768.8)0.065
Perioperative complications
    POPF58 (65.9)38 (59.4)20 (83.3)0.044
    Gastrointestinal fistula5 (5.7)4 (6.2)1 (4.2)1
    Bile leakage5 (5.7)9 (14.1)5 (20.8)0.516
    Intra-abdominal infection43 (48.9)27 (42.2)16 (66.7)0.056
Hemorrhage details
    Bleeding latency, days15 (11-23)15 (10-23)17.5 (13.2-19.5)0.422
    Hemoglobin concentration(g/L)74.7 ± 15.775.2 ± 14.873.5 ± 18.30.688
    PLT (109/L)250.6 ± 101.9262.2 ± 90.8219.5 ± 123.70.133
    APTT (s)32.8 (27.6-41.8)32.3 (26.5-39.3)37.1 (30.2-49.8)0.037
    INR1.2 (1.1-1.3)1.1 (1.1-1.2)1.3 (1.2-1.7)< 0.001
Coagulopathy31 (35.2)17 (26.6)14 (58.3)0.011
Severity of PPH0.088
    Grade B36 (40.9)30 (46.9)6 (25)
    Grade C52 (59.1)34 (53.1)18 (75)


Write to the Help Desk